[go: up one dir, main page]

WO2006119758A3 - Derivate von dihydroxyphenylalanin - Google Patents

Derivate von dihydroxyphenylalanin Download PDF

Info

Publication number
WO2006119758A3
WO2006119758A3 PCT/DE2006/000830 DE2006000830W WO2006119758A3 WO 2006119758 A3 WO2006119758 A3 WO 2006119758A3 DE 2006000830 W DE2006000830 W DE 2006000830W WO 2006119758 A3 WO2006119758 A3 WO 2006119758A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
syndrome
dihydroxyphenylalanine
derivatives
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2006/000830
Other languages
English (en)
French (fr)
Other versions
WO2006119758A2 (de
WO2006119758B1 (de
Inventor
Gisela Susilo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ellneuroxx Ltd
Original Assignee
Ellneuroxx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellneuroxx Ltd filed Critical Ellneuroxx Ltd
Priority to US11/914,207 priority Critical patent/US20090285888A1/en
Priority to CA002607198A priority patent/CA2607198A1/en
Priority to EP06742338A priority patent/EP1879880A2/de
Priority to JP2008510404A priority patent/JP2008540465A/ja
Publication of WO2006119758A2 publication Critical patent/WO2006119758A2/de
Publication of WO2006119758A3 publication Critical patent/WO2006119758A3/de
Publication of WO2006119758B1 publication Critical patent/WO2006119758B1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die Erfindung betrifft Derivate von Dihydroxyphenylalanin, deren Herstellung sowie pharmazeutischθ Zusammensetzungen enthaltend diese Derivate von Dihydroxyphenylalanin. Ferner betrifft die Erfindung die Verwendung dieser Derivate von Dihydroxyphenylalanin sowie der pharmazeutischen Zusammensetzungen zur Behandlung und Prophylaxe von Bewegungsstorungen, neurodegenerativen Erkrankungen, Alzheimer, Parkinson'schen Krankheit, Hemiatrophie-Hemiparkinson, Parkinsonsyndrom, Lewy-Körperchen Krankheit, frontotemporale Demenz, Lytico-Bodig Krankheit (Parkinsonismus-Demenz-amyotrophe Lateralsklerose), striatonigrale Degeneration, Shy-Drager-Syndrom, sporadische olivo-ponto-cerebellare Degeneration, progressive pallidale Atrophie, fortschreitende supranukleare Lahmung (progressive supranuclear palsy), Hallervorden-Spatz Erkrankung, Huntington'sche Krankheit, x-Chromosom verknËpfte Dystonie (Morbus Lubag), mitochondriale Zytopathie mit striataler Nekrose, Neuroakanthocytose, Restless Leg Syndrom, Wilson'sche Krankheit.
PCT/DE2006/000830 2005-05-13 2006-05-14 Derivate von dihydroxyphenylalanin Ceased WO2006119758A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/914,207 US20090285888A1 (en) 2005-05-13 2006-05-14 Derivatives of dihydroxyphenylalanine
CA002607198A CA2607198A1 (en) 2005-05-13 2006-05-14 Dihydroxyphenylalanine derivatives
EP06742338A EP1879880A2 (de) 2005-05-13 2006-05-14 Derivate von dihydroxyphenylalanin
JP2008510404A JP2008540465A (ja) 2005-05-13 2006-05-14 ジヒドロキシフェニルアラニン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005022276A DE102005022276A1 (de) 2005-05-13 2005-05-13 Derivate von Dihydroxyphenylalanin
DE102005022276.5 2005-05-13

Publications (3)

Publication Number Publication Date
WO2006119758A2 WO2006119758A2 (de) 2006-11-16
WO2006119758A3 true WO2006119758A3 (de) 2007-03-22
WO2006119758B1 WO2006119758B1 (de) 2007-05-24

Family

ID=37158955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/000830 Ceased WO2006119758A2 (de) 2005-05-13 2006-05-14 Derivate von dihydroxyphenylalanin

Country Status (7)

Country Link
US (1) US20090285888A1 (de)
EP (1) EP1879880A2 (de)
JP (1) JP2008540465A (de)
CN (1) CN101208326A (de)
CA (1) CA2607198A1 (de)
DE (1) DE102005022276A1 (de)
WO (1) WO2006119758A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121070A1 (en) 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
JP4781352B2 (ja) 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
CN101365439B (zh) 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
ITMI20081167A1 (it) * 2008-06-26 2009-12-27 Ctg Pharma S R L Composizioni farmaceutiche per il trattamento di malattie neurodegenerative
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
AU2011337596B2 (en) 2010-12-02 2016-07-07 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (de) 2014-09-29 2020-03-18 Cellix Bio Private Limited Verbindungen und zusammensetzungen zur behandlung multipler sklerose
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
AU2016314617A1 (en) * 2015-09-02 2018-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
US20210380525A1 (en) * 2018-10-08 2021-12-09 Cellix Bio Provate Limited Compositions and methods for the treatment of parkinson's disease
CN110041300A (zh) * 2019-02-18 2019-07-23 海南大学 一种医药中间体化合物及其合成方法
US20220213128A1 (en) * 2021-01-03 2022-07-07 RockGen Therapeutics LLC L-Dopa Enhanced with a Neuroprotective Agent as a Therapy for Parkinson's Disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
EP0352815A1 (de) * 1988-07-29 1990-01-31 ZAMBON GROUP S.p.A. Dopamin-Vorläufer
WO2003043974A2 (en) * 2001-11-19 2003-05-30 Orion Corporation New pharmaceutical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH562199A5 (de) * 1970-10-30 1975-05-30 Hoffmann La Roche
DE19619510A1 (de) * 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
EP0352815A1 (de) * 1988-07-29 1990-01-31 ZAMBON GROUP S.p.A. Dopamin-Vorläufer
WO2003043974A2 (en) * 2001-11-19 2003-05-30 Orion Corporation New pharmaceutical compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. DI STEFANO ET AL.: "L-Dopa- and Dopmaine-(R)-alpha-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, 23 February 2006 (2006-02-23), pages 1486 - 1493, XP002405330 *
BODOR ET AL.: "Improved Delivery through Biological Membranes. 4. Prodrugs of L-Dopa", JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 11, 1977, pages 1435 - 1445, XP002405327 *
ISHIDA ET AL.: "Synthesis of 3,4-Dihydro- and 1,2,3,4-Tetrahydroisoquinolines", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 34, no. 5, 1986, pages 1994 - 2006, XP008070776 *
M.J. ADAM ET AL.: "Reaction of [18F]acetyl hypofluorite with derivatives of dihydroxyphenylalanine: synthesis of L-18F"6-fluorodopa", APPLIED RADIATION AND ISOTOPES, vol. 37, no. 8, 1986, pages 877 - 882, XP002405328 *

Also Published As

Publication number Publication date
CA2607198A1 (en) 2006-11-16
CN101208326A (zh) 2008-06-25
US20090285888A1 (en) 2009-11-19
JP2008540465A (ja) 2008-11-20
WO2006119758A2 (de) 2006-11-16
EP1879880A2 (de) 2008-01-23
WO2006119758B1 (de) 2007-05-24
DE102005022276A1 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
WO2006119758A3 (de) Derivate von dihydroxyphenylalanin
NZ592881A (en) Quinolone compound and pharmaceutical composition
MD4081F2 (en) Polymorphous forms of rifaximin, processes for their production and use as medicinal preparations with antibiotic action
NZ748983A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
ECSP11011051A (es) Nuevos compuestos 578
JP2017508741A5 (de)
WO2006091496A3 (en) Benzazole potentiators of metabotropic glutamate receptors
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2015095223A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2018015573A3 (en) Trem2 cleavage modulators and uses thereof
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
WO2008063232A3 (en) Substituted pyrazolopyrimidines
PH12021552217A1 (en) Macrocyclic azolopyridine derivatives as eed and prc2 modulators
TN2009000447A1 (en) An extented-release composition comprising a somatostatin derivative in microparticles
MD20160102A2 (ro) Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
WO2011084685A3 (en) Saposin-a derived peptides and uses thereof
MX2010013451A (es) Composiciones farmaceuticas que comprenden derivados de aminociclohexano.
WO2014047257A3 (en) Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
WO2005074981A8 (en) Inhibitors of tgf-r signaling for treatment of cns disorders
NZ593279A (en) Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
SV2006002073A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos ref. pc 32080a
MY167668A (en) Uses of recombinant super-compound interferons
MX2007011211A (es) Derivados de tiazol fusionado que tienen afinidad para el receptor h3 de histamina.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006742338

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2607198

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008510404

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 9490/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200680022936.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006742338

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914207

Country of ref document: US